162 related articles for article (PubMed ID: 38366083)
21. Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment.
Kong C; Xu B; Qiu G; Wei M; Zhang M; Bao S; Tang J; Li L; Liu J
Int J Nanomedicine; 2022; 17():5391-5411. PubMed ID: 36419717
[TBL] [Abstract][Full Text] [Related]
22. Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosus.
Jiao Q; Qian Q; Zhao Z; Fang F; Hu X; An J; Wu J; Liu C
Arch Dermatol Res; 2016 Oct; 308(8):553-61. PubMed ID: 27394439
[TBL] [Abstract][Full Text] [Related]
23. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
24. Low Distribution of TIM-3
Zhuang C; Ni B; Zhang ZZ; Zhao WY; Tu L; Ma XL; Yang LX; Cao H; Wang M
J Immunol Res; 2021; 2021():6647292. PubMed ID: 33681387
[TBL] [Abstract][Full Text] [Related]
25. Precision USPIO-PEG-SLe
Li T; Guo L; Li J; Mu X; Liu L; Song S; Luo N; Zhang Q; Zheng B; Jin G
Int J Nanomedicine; 2024; 19():1249-1272. PubMed ID: 38348177
[TBL] [Abstract][Full Text] [Related]
26. Photothermal-Activatable Fe
Ge R; Liu C; Zhang X; Wang W; Li B; Liu J; Liu Y; Sun H; Zhang D; Hou Y; Zhang H; Yang B
ACS Appl Mater Interfaces; 2018 Jun; 10(24):20342-20355. PubMed ID: 29878757
[TBL] [Abstract][Full Text] [Related]
27. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
28. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
[TBL] [Abstract][Full Text] [Related]
29. Oridonin Could Inhibit Inflammation and T-cell Immunoglobulin and Mucin-3/Galectin-9 (TIM-3/Gal-9) Autocrine Loop in the Acute Myeloid Leukemia Cell Line (U937) as Compared to Doxorubicin.
Nasri F; Sadeghi F; Behranvand N; Samei A; Bolouri MR; Azari T; Abdollahi E; Ghazizadeh F; Motevalian M; Hassan ZM; Falak R
Iran J Allergy Asthma Immunol; 2020 Dec; 19(6):602-611. PubMed ID: 33463129
[TBL] [Abstract][Full Text] [Related]
30. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.
Li Z; Liu X; Guo R; Wang P
Tumour Biol; 2017 May; 39(5):1010428317698352. PubMed ID: 28475007
[TBL] [Abstract][Full Text] [Related]
31. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
32. Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements.
Meggyes M; Nagy DU; Balassa T; Godony K; Peterfalvi A; Szereday L; Polgar B
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439744
[TBL] [Abstract][Full Text] [Related]
33. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
34. PTPN2 regulates the generation of exhausted CD8
LaFleur MW; Nguyen TH; Coxe MA; Miller BC; Yates KB; Gillis JE; Sen DR; Gaudiano EF; Al Abosy R; Freeman GJ; Haining WN; Sharpe AH
Nat Immunol; 2019 Oct; 20(10):1335-1347. PubMed ID: 31527834
[TBL] [Abstract][Full Text] [Related]
35. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes.
Kanzaki M; Wada J; Sugiyama K; Nakatsuka A; Teshigawara S; Murakami K; Inoue K; Terami T; Katayama A; Eguchi J; Akiba H; Yagita H; Makino H
Endocrinology; 2012 Feb; 153(2):612-20. PubMed ID: 22186414
[TBL] [Abstract][Full Text] [Related]
36. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.
Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892
[TBL] [Abstract][Full Text] [Related]
37. Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury.
Liu Y; Ji H; Zhang Y; Shen X; Gao F; He X; Li GA; Busuttil RW; Kuchroo VK; Kupiec-Weglinski JW
J Hepatol; 2015 Mar; 62(3):563-72. PubMed ID: 25450716
[TBL] [Abstract][Full Text] [Related]
38. Effect of the use of Galectin-9 and blockade of TIM-3 receptor in the latent cellular reservoir of HIV-1.
Sanz M; Madrid-Elena N; Serrano-Villar S; Vallejo A; Gutiérrez C; Moreno S
J Virol; 2021 Mar; 95(5):. PubMed ID: 33361434
[TBL] [Abstract][Full Text] [Related]
39. Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4
Zhuo Y; Zhang YF; Wu HJ; Qin L; Wang YP; Liu AM; Wang XH
Biomed Pharmacother; 2017 Oct; 94():386-393. PubMed ID: 28772217
[TBL] [Abstract][Full Text] [Related]
40. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
Van Woensel M; Mathivet T; Wauthoz N; Rosière R; Garg AD; Agostinis P; Mathieu V; Kiss R; Lefranc F; Boon L; Belmans J; Van Gool SW; Gerhardt H; Amighi K; De Vleeschouwer S
Sci Rep; 2017 Apr; 7(1):1217. PubMed ID: 28450700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
